Unlock instant, AI-driven research and patent intelligence for your innovation.
Fluoro-alkyl-cyclopeptide derivatives having anti-integrin activity
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A compound and drug technology, applied in the field of fluoro-alkyl-cyclic peptide derivatives, can solve problems affecting proteolytic stability and solubility
Inactive Publication Date: 2005-08-31
SIGMA TAU IND FARMACEUTICHE RIUNITE SPA
View PDF5 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Moreover, the substitution of fluorine for hydrogen may affect the proteolytic stability and solubility of peptides containing it (Koksch, B., J. Pept. Sci., 1997, 3, 157-67)
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0079] C(Arg-Glv-Asp-D-Phe-(R or S)-Tfm-Phe) (ST1930 / ST1931)
[0080] Preparation of Pht-D-Phe-Br (Dal Pozzo, A., Bergonzi, R. and Ni, M.H., Tetrahedron Lett., 2001, 42, 3925-7).
[0081] 1.4 g (4.75 mmol) Pht-D-Phe-OH were dissolved in 19 ml of a 0.5 M solution of bromoenamine in DCM under argon. After 10 minutes, the solution is ready to use.
[0082] Add 248mg (0.950mmol) of H-α-Tfm-Phe-OEt and collidine (1 equivalent) to 12.5ml of bromide solution (prepared as above) cooled to 0°C, stir the mixture at room temperature (a.t.), after 10 minutes Another 6.5 ml portion of the bromide solution and 1 equivalent of collidine were added. After 2 h the mixture was dried with 15 ml of 5% NaHCO 3 and 15 ml EtOAc, and stirred for 30 minutes. The solvent was washed with water, 1N HCl and water, then evaporated and the residue was purified on a flash column using 8:2 hexane-EtOAc as solvent.
[0083] 4.3ml of 1M BBr 3 The DCM solution of 460 mg of dipeptide Pht-D-Phe-α-Tfm-Phe-O...
[0111] Proceed as described in Example 1 starting from H-(R,S)-Dfm-Phe-OEt. A mixture of the two diastereoisomers was obtained which had not yet been resolved.
[0116] c(Arg-Gly-(R or S)-Tfm-Asp-D-Phe-Val)(ST2189 / 2190)
[0117] H-(R,S)-Tfm-Allgly-Oet was condensed with Pth-Gly-Br and then worked up as described in Example 1. With preparative HPLC, containing 22% CH 3 CN in water + 0.1% TFA resolved and purified the mixture of two diastereoisomers.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
Compounds of formula (I) cyclo [NX1-R1-CO-NX2-R2-CO-NX3-R3-CO-NX4-CO-NX5-R5-CO], wherein at least one x-fluoroalkylated amino acid is present, are inhibitors of integrins, particularly those belonging to the alphavbeta3 and alphavbeta5 family, and thus are useful as medicaments, particularly for the treatment of the underlying diseases responsible for abnormal angiogenesis, such as retinopathy, acute kidney failure, osteoporosis and metastases. The compounds described herein are also useful as diagnostic agents, when appropriately labelled, especially for the detection and location of small tumour masses and arterial occlusion events.
Description
[0001] The invention described here relates to fluoro-alkyl-cyclic peptide derivatives having anti-integrin activity, in particular to cyclic peptide compounds containing a fluoro-alkyl group at the nitrogen and / or C-alpha position of the peptide bond, as follows Shown in the formula (I). The invention described here also relates to processes for the preparation of said compounds, their use as medicaments, especially as integrin receptor inhibitors, as anti-angiogenic and anti-metastatic agents, and to pharmaceutical compositions comprising them. Background of the invention [0002] Integrins are a class of receptors involved in the phenomenon of cell adhesion. They are glycoproteins composed of two subunits, D and β, that combine to form distinct families. For a more detailed description see Kessler, H., et al., Angew. Chem. Int. Ed. Engl., 1997, 36, 1374-89. [0003] All integrins have a "universal cellular recognition site" that recognizes the common peptide sequence Arg-...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.